Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Antiaging Quantum Living Inc AAQL

Antiaging Quantum Living Inc. is an investment holding company. It focuses on Website development, maintenance and online business advertisement. Its primary business operations are conducted through its subsidiaries AAQL Inc., AAQL HK Limited, Antiaging Doctor Hangzhou Holding LTD (Dao Ling Doctor Hangzhou), Dao Ling Doctor (Zhejiang) Health Management Limited (Dao Ling Doctor Zhejiang), and... see more

Recent & Breaking News (OTCPK:AAQL)

Mid-Morning Market Update: Markets Open Lower; Disney Earnings Beat Views

Benzinga.com  August 9, 2017

Achillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor

GlobeNewswire August 8, 2017

Investor Network: Achillion Pharmaceuticals, Inc. to Host Earnings Call

Accesswire August 8, 2017

Achillion to Host Second Quarter 2017 Results Conference Call on August 8, 2017

GlobeNewswire August 1, 2017

Achillion Pharmaceutials Announces Key Promotion and Discovery Organization Change

GlobeNewswire July 10, 2017

Stocks Under Scanner in the Biotech Space -- Achillion Pharma, Kite Pharma, Acorda Therapeutics, and Tesaro

PR Newswire July 6, 2017

Achillion to Present at the 2017 JMP Securities Life Sciences Conference

GlobeNewswire June 15, 2017

Achillion to Present at the Jefferies 2017 Global Healthcare Conference

GlobeNewswire June 5, 2017

Mid-Day Market Update: Crude Oil Down 1%; Forestar Shares Spike Higher

Benzinga.com  June 5, 2017

Biotech Stocks on Investors' Radar -- Achillion Pharma, Acorda Therapeutics, Aralez Pharma, and Regulus Therapeutics

PR Newswire May 26, 2017

15 Biggest Mid-Day Gainers For Thursday

Benzinga.com  May 18, 2017

Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs

GlobeNewswire May 4, 2017

Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference

GlobeNewswire May 2, 2017

Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178

GlobeNewswire April 22, 2017

Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria

GlobeNewswire April 6, 2017

Biotech Stocks Under Scanner -- Celsion, Achillion Pharma, Tenax Therapeutics, and Cerulean Pharma

PR Newswire March 29, 2017

USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pathway Factor D Inhibitors

GlobeNewswire March 21, 2017

Achillion Pharmaceuticals to Support a Natural History Study of C3 Glomerulopathy, a Rare Renal Disorder, Conducted by Experts at Imperial College London

GlobeNewswire February 28, 2017

Achillion Reports 2016 Fourth Quarter and Year-End Financial Results

GlobeNewswire February 23, 2017

Biotech Stocks Under Scanner -- Celldex Therapeutics, Achillion Pharma, Vertex Pharma, and Concordia

PR Newswire February 17, 2017